Clinical Study on Treatment of 82 Patients with the Recurrence of Henoch-Schonle in Purpura by Bacille Calmette-guerin Polysaccharide Nucleic Acid

OBJECTIVE To observe the clinical effect of bacille calmette-guerin polysaccharide nucleic acid (BCG-PSN) for prevention of the recurrence of Henoch-Schonlein purpura(HSP) and analyze its related factors. METHODS Eighty-two children were divided randomly into the treatment group (46) and the control group (36), the former was treated with common therapy and BCG-PSN (0.5mg, twice a week for 3 months, im), and the latter was treated only with common therapy. Another 33 healthy children were served as normal control group. Observe the rate of recurrence in hospitalization in a year, and determined the level of CD₃⁺, CD₄⁺, CD₈⁺, IL-2, IFN-γ, IgA before and after 3 months′ treatment. RESULTS Before treatment, the level of CD₃⁺, CD₄⁺, IL-2, IFN-γ in the treatment group were lower than those in normal control group (P<0.01), and the level of IgA was higher than those in normal control group(P<0.01). Three months after treatment, the level of CD₃⁺, CD₄⁺, CD₈⁺, IL-2, IFN-γ, IgA in the treatment group recovery better than those in the control group significantly (P<0.01 or P<0.05), there was no difference between the treatment group and the normal control group (P<0.05). The rate of recurrence in the treatment group was lower than that in the control group in a year (P<0.05). CONCLUSION BCG-PSN can adjust the immune function and lower the recurrence of HSP.